How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

65,172 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years

A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years 1 Version 3, Oct 2018 Review 2021 Authors: ACDC Guideline Development Group N Wright, SM Ng, JC Agwu, P Adolfsson, J Drew, J Pemberton, M Kershaw, S Bissell, C Moudiotis, F Regan, C Gardner, A Astle, A Adams, G Adams, P Manning, A Timmis, A Soni, E Williams ssociation of Children ’s Diabetes Clinicians (...) FOR STAFF Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus PATIENTS Children and young people with diabetes mellitus This guideline is intended for use in managing continuous glucose monitoring (CGM) or real-time flash glucose scanning (FGS) for all children and young people under 18 years with Type 1 diabetes mellitus. Table of Contents Introduction 2 Overview of Pertinent NICE guidance 3 Devices Available for CGM and FGS 6 Section 1: Evidence

2018 British Society for Paediatric Endocrinology and Diabetes

22. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. (PubMed)

Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Many adults with type 2 diabetes mellitus (T2DM) experience a psychosocial burden and mental health problems associated with the disease. Diabetes-related distress (DRD) has distinct effects on self-care behaviours and disease control. Improving DRD in adults with T2DM could enhance psychological well-being, health-related quality of life, self-care abilities and disease control, also reducing (...) depressive symptoms.To assess the effects of psychological interventions for diabetes-related distress in adults with T2DM.We searched the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, BASE, WHO ICTRP Search Portal and ClinicalTrials.gov. The date of the last search was December 2014 for BASE and 21 September 2016 for all other databases.We included randomised controlled trials (RCTs) on the effects of psychological interventions for DRD in adults (18 years and older) with T2DM. We included trials

2017 Cochrane

23. Diabetes Stewardship – Pharmaceutical care of adolescents with type 1 diabetes mellitus provided by community pharmacists. (PubMed)

Diabetes Stewardship – Pharmaceutical care of adolescents with type 1 diabetes mellitus provided by community pharmacists. Diabetes mellitus Type 1 is one of the most common diseases in childhood. Severe, secondary diseases like hypertension or blindness are results of micro- and macrovascular complications caused by insufficient glycaemic control. Especially adolescent patients with type 1 diabetes have a lower adherence rate. The DIADEMA trial proved that community pharmacist (...) in collaboration with diabetologists and diabetes advisors can have a positive impact on the therapy of adolescents with type 1 diabetes. This article highlights and explains which components of the pharmacist intervention caused the preferable adjustments and improved the insulin therapy of the patients.

2018 Medizinische Monatsschrift fur Pharmazeuten Controlled trial quality: uncertain

24. Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus

Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Type 1 diabetes happens when the cells that make insulin in the pancreas, the islets, are destroyed. Islet cell transplantation involves extracting islet cells from the pancreas

2016 Health Technology Assessment (HTA) Database.

25. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review

Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 15(16). 2015 Authors' conclusions Islet transplantation offers an alternative for patients with type 1 diabetes who have brittle diabetes with difficult-to-control blood glucose levels or hypoglycemic unawareness despite optimal insulin therapy. Treatment

2016 Health Technology Assessment (HTA) Database.

26. Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation

Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). OHTAC Recommendation. 2015 Authors' conclusions OHTAC members acknowledged that there was uncertainty in the evidence that islet transplantation improved secondary complications of diabetes and quality of life. However, OHTAC also recognized that patients being treated with islet transplantation had a very complicated form

2016 Health Technology Assessment (HTA) Database.

27. Patient perspectives on quality of life with cncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis

Patient perspectives on quality of life with cncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series. 2015 Authors' conclusions Serious consequences of type 1

2016 Health Technology Assessment (HTA) Database.

28. Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2

Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2 insulin degludec + liraglutide | CADTH.ca Find the information you need insulin degludec + liraglutide insulin degludec + liraglutide Last Updated: October 3, 2019 Result type: Reports Project Number: SR0599-000 Product Line: Generic Name: insulin degludec + liraglutide Brand Name: Xultophy Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control. Submission Type: New Combination Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

29. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus

Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular (...) , fasting laboratories after overnight glycemic control, and insulin sensitivity by hyperinsulinemic-euglycemic clamp (glucose infusion rate/insulin). Adolescents with T1DM were randomized 1:1 to 3 months of 2000 mg metformin or placebo daily, after which baseline measures were repeated.Forty-eight adolescents with T1DM who were 12 to 21 years of age (40% body mass index [BMI] ≥90th percentile; 56% female) and 24 nondiabetic control participants of similar age, BMI, and sex distribution were enrolled

Full Text available with Trip Pro

2019 EvidenceUpdates

30. A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 Years

A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 Years 1 Version 2, April 2017 Review 2020 Authors: ACDC Guideline Development Group N Wright, SM Ng, JC Agwu, P Adolfsson, J Drew, J Pemberton, M Kershaw, S Bissell, C Moudiotis, F Regan, C Gardner, A Astle, A Adams, G Adams, P Manning, A Timmis, A Soni, E Williams ssociation of Children’s Diabetes Clinicians (...) Clinicians FOR STAFF Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus PATIENTS Children and young people with diabetes mellitus This guideline is intended for use in managing continuous glucose monitoring (CGM) or real-time flash glucose scanning (FGS) for all children and young people under 18 years with Type 1 diabetes mellitus. Table of Contents Introduction 2 Overview of Pertinent NICE guidance 3 Devices Available for CGM and FGS 6 Section 1

2017 British Society for Paediatric Endocrinology and Diabetes

31. Digital health interventions for diabetes self-management education/support in type 1 & 2 diabetes mellitus

Digital health interventions for diabetes self-management education/support in type 1 & 2 diabetes mellitus Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary

2019 PROSPERO

32. Glucagon-like peptide (GLP)-1 analogues as an add-on to insulin for adults with type 1 diabetes mellitus [Cochrane protocol]

Glucagon-like peptide (GLP)-1 analogues as an add-on to insulin for adults with type 1 diabetes mellitus [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) : Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2019 PROSPERO

33. No subpopulation exhibit greater cardiovascular benefits from long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (DM): a systematic review and meta-analysis of cardiovascular outcome trials

No subpopulation exhibit greater cardiovascular benefits from long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (DM): a systematic review and meta-analysis of cardiovascular outcome trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate (...) : 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text

2019 PROSPERO

40. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. (PubMed)

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Intermediate hyperglycaemia (IH) is characterised by one or more measurements of elevated blood glucose concentrations, such as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c). These levels are higher than normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). The reduced threshold of 5.6 mmol/L (100 mg/dL) fasting plasma (...) glucose (FPG) for defining IFG, introduced by the American Diabetes Association (ADA) in 2003, substantially increased the prevalence of IFG. Likewise, the lowering of the HbA1c threshold from 6.0% to 5.7% by the ADA in 2010 could potentially have significant medical, public health and socioeconomic impacts.To assess the overall prognosis of people with IH for developing T2DM, regression from IH to normoglycaemia and the difference in T2DM incidence in people with IH versus people

2018 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>